Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;8(1):150-158.
doi: 10.1177/1932296813516956. Epub 2014 Jan 1.

Does Device Make Any Difference? A Real-world Retrospective Study of Insulin Treatment Among Elderly Patients With Type 2 Diabetes

Raymond Miao  1 , Wenhui Wei  2 , Jay Lin  3 , Lin Xie  4 , Onur Baser  5
Affiliations

Does Device Make Any Difference? A Real-world Retrospective Study of Insulin Treatment Among Elderly Patients With Type 2 Diabetes

Raymond Miao et al. J Diabetes Sci Technol. 2014 Jan.

Abstract

We compared real-world clinical and economic outcomes for insulin glargine treatment administered by disposable pen and traditional vial-and-syringe injections among elderly patients with type 2 diabetes mellitus (T2DM). Using a large database of US retirees, this retrospective longitudinal study examined 1-year follow-up outcomes in patients with T2DM aged 65 years or older who were either insulin naïve and initiated insulin glargine via disposable pen (pen initiators [PI]) or vial (vial initiators [VI]) or were already insulin glargine users but either continued with a vial (vial continuers [VC]) or switched to a disposable pen (pen switchers [PS]). There were 7856 propensity-score-matched patients, including 2930 each in the PI and VI cohorts, and 998 each in the VC and PS cohorts. Compared with vial-and-syringe users, the disposable pen users had significantly greater treatment persistence (P < .0001 for both comparisons), duration of persistence (P < .0001 for both), and adherence (P < .01 for both) and lower insulin daily average consumption (P < .05 for both). Compared with the VI cohort, the PI cohort had significantly fewer hypoglycemia-related events (P = .0164). Total health care costs were comparable for the respective matched cohorts. In elderly patients with T2DM receiving insulin glargine therapy, initiating or switching to a disposable pen was associated with better treatment persistence and adherence than initiating or continuing with vial-and-syringe, without increased total health care costs. Among insulin-naïve patients, initiating insulin glargine by disposable pen was also associated with significantly reduced risk of hypoglycemia compared with vial-and-syringe patients.

Keywords: elderly; insulin glargine; pen; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RM and WW: employees of Sanofi US, Inc. JL: employee at Novosys Health, which received funding to carry out this work from Sanofi US, Inc. LX and OB: employees at STATinMed, which received funding to carry out this work from Sanofi US, Inc.

Figures

Figure 1a.
Figure 1a.
Kaplan–Meier curve for the time to treatment discontinuation for insulin-glargine-naïve patients.
Figure 1b.
Figure 1b.
Kaplan–Meier curve for the time to treatment discontinuation for insulin-glargine-experienced patients.
Figure 2a.
Figure 2a.
Health care costs associated with initiating treatment with insulin glargine by pen device or vial-and-syringe injections, 1-year follow-up of insulin-glargine-naïve patients. ED, emergency department.
Figure 2b.
Figure 2b.
Health care costs associated with initiating treatment with insulin glargine by pen device or vial-and-syringe injections, 1-year follow-up of insulin-glargine-experienced patients. ED, emergency department.
See this image and copyright information in PMC

References

    1. International Diabetes Foundation. Risk factors, 2011. www.idf.org/about-diabetes/risk-factors. Accessed January 6, 2012.
    1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed January 6, 2012.
    1. Resnick HE, Heineman J, Stone R, Shorr RI. Diabetes in U.S. nursing homes, 2004. Diabetes Care. 2008;31(2):287-288. - PubMed
    1. Russell LB, Valiyeva E, Roman SH, Pogach LM, Suh DC, Safford MM. Hospitalizations, nursing home admissions, and deaths attributable to diabetes. Diabetes Care. 2005;28(7):1611-1617. - PubMed
    1. American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35(suppl 1):S11-S63. - PMC - PubMed

LinkOut - more resources